A simple screening method for detecting gastrointestinal protein loss in intestinal lymphangiectasia
Related Experiment Videos
Insights
A novel diagnostic approach for protein losing enteropathy was identified using Patent Blue dye. This method aids in detecting intestinal lymphangiectasia and lymphoenteric fistulas in pediatric patients.
Area of Science:
- Pediatric Gastroenterology
- Diagnostic Imaging
- Lymphatic System Abnormalities
Background:
- Protein losing enteropathy (PLE) in infants presents with symptoms like diarrhea, edema, and hypoproteinemia.
- Gastrointestinal protein loss is often linked to lymphatic system dysfunction, specifically intestinal lymphangiectasia.
- Conventional diagnostic methods like lymphangiography may be limited by patient factors such as lymphatic hypoplasia.
Observation:
- A 10-month-old child with severe PLE symptoms was investigated.
- Standard lymphangiography was unsuccessful due to underdeveloped peripheral lymphatics.
- Patent Blue dye administered intradermally appeared in the patient's stools within hours.
Findings:
- The presence of Patent Blue dye in stool strongly suggests an intestinal lymphoenteric fistula.
- This indicates abnormal communication between lymphatic vessels and the gastrointestinal tract.
- The dye's appearance provides a direct visual link for diagnosing gastrointestinal protein loss.
Implications:
- This observation presents a potential new diagnostic test for protein losing enteropathy.
- The Patent Blue dye method offers a less invasive alternative when lymphangiography is not feasible.
- This technique could improve the diagnosis and management of pediatric intestinal lymphangiectasia.
Abstract:
A ten month old female Turkish child with chylous ascites, diarrhea, steatorrhea, peripheral edema and hypoproteinemia was investigated for protein losing enteropathy which probably dated from the first weeks of life. Gastrointestinal protein loss appeared to be due to abnormalities of the intestinal lymphatics. In order to detect a localized lymphoenteric fistula, lymphangiography was tried but failed due to hypoplasia of peripheral lymphatics. However, three hours after intradermal injection of Patent Blue, the dye appeared in the stools of the patient, suggesting intestinal protein loss via a lympho-enteric fistula. This observation may provide the basis for a diagnostic test for gastro-intestinal protein loss in patients with intestinal lymphangiectasia.